Medical Instruments & Supplies: Antares Pharma (NASDAQ:ATRS), Covidien plc (NYSE:COV), Baxter International (NYSE:BAX), Becton, Dickinson and Co. (NYSE:BDX)

Antares Pharma (Nasdaq:ATRS) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and deteriorating net income. Antares Pharma Inc (NASDAQ:ATRS) shares after opening at $2.98 moved to $3.06 on last trade day and at the end of the day closed at $2.91. Company price to sales ratio in past twelve months was calculated as 18.35 and price to cash ratio as 5.99. Antares Pharma Inc (NASDAQ:ATRS) showed a negative weekly performance of -11.01%.

Covidien PLC (NYSE:COV) stock had its “unbiased” rating reaffirmed in an examination note issued on Tuesday, Analyst RN reports. They right now have a $77.00 value focus on the stock. Scientist’s target cost recommends a potential upside of 4.53% from the organization’s current cost. Covidien plc (NYSE:COV) shares fell -0.03% in last trading session and ended the day on $69.90. COV return on equity ratio is recorded as 21.40% and its return on assets is 10.20%. Covidien plc (NYSE:COV) yearly performance is 20.56%.

Baxter International (NYSE:BAX) will announce its Q114 earnings results on Thursday, April 17th. Analysts expect the company to announce earnings of $1.09 per share and revenue of $3.88 billion for the quarter. Baxter International has set its Q1 guidance at $1.06-1.09 EPS and its FY14 guidance at $5.05-5.25 EPS.Investors that are interested in participating in the company’s conference call can do so using this link. Baxter International Inc. (NYSE:BAX) shares moved up 0.82% in last trading session and was closed at $73.36, while trading in range of $72.13-$73.48. Baxter International Inc. (NYSE:BAX) year to date performance is 6.23%.

ISI Group increased their target price on shares of Becton Dickinson & Co. (NYSE:BDX) from $123.00 to $130.00 in a research note issued on Monday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. ISI Group’s price objective would indicate a potential upside of 11.74% from the company’s current price. Becton, Dickinson and Co. (NYSE:BDX) weekly performance is 0.01%. On last trading day company shares ended up $113.76. Becton, Dickinson and Co. (NYSE:BDX) distance from 50-day simple moving average is -0.18%. Analysts mean target price for the company is $117.64.